Avenue Therapeutics, Inc. (ATXI) 2021年年度报告「NASDAQ」.pdf

1、Table of ContentsUNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington,D.C.20549FORM 10-KANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the Fiscal Year Ended December 31,2021orTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、OF 1934For the Transition Period from to .Commission File Number 001-38114AVENUE THERAPEUTICS,INC.(Exact name of registrant as specified in its charter)Delaware 47-4113275(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)1140 Avenue of the Americas,Floo

3、r 9,New York NY 10036(Address of principal executive offices and zip code)(781)652-4500(Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:(Title of Class)Trading Symbol(s)(Name of exchange on which registered)Common Stock,par value$0.0001 per

4、share ATXINasdaq Global MarketSecurities registered pursuant to section 12(g)of the Act:None.Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant

5、to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrantwas required to file su

6、ch reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or